Laura Segundo-San
Salamanca, CL, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Neutrophil-mediated trogocytosis as a new mechanism of action of daratumumab.
Journal: Blood neoplasia
Published: February 11, 2025
EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
Journal: Neuro-oncology
Published: March 20, 2024
Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.
Journal: International journal of molecular sciences
Published: March 14, 2024
Chloroquine-Induced DNA Damage Synergizes with Nonhomologous End Joining Inhibition to Cause Ovarian Cancer Cell Cytotoxicity.
Journal: International journal of molecular sciences
Published: May 24, 2022
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
Journal: Cells
Published: December 23, 2020
Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma.
Journal: Cancers
Published: August 31, 2020
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.
Journal: Nature communications
Published: October 09, 2019
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Journal: Haematologica
Published: July 20, 2019
Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Journal: Oncotarget
Published: July 05, 2017
C3G promotes a selective release of angiogenic factors from activated mouse platelets to regulate angiogenesis and tumor metastasis.
Journal: Oncotarget
Published: July 05, 2017
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
Journal: Journal of hematology & oncology
Published: April 04, 2017
Last Updated: 09/26/2026